Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...

The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) climbed 5.5% Tuesday as the U.S. Food and Drug Administration approved ...

1 “ONAPGO represents a novel approach for adults with Parkinson’s disease who are experiencing motor fluctuations,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals.

Commenting on the new labeling, Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals, said, “By expanding Qelbree’s label to include new data on the pharmacodynamics and ...

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq ...

ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company specializing in CNS diseases with an impressive 89% gross profit margin, has announced the FDA approval of a ...

Supernus Pharmaceuticals ... The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.